Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Manuel Galán Gutiérrez"'
Autor:
Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Marta Cebolla-Verdugo, Alvaro Prados-Carmona, Carlos Hernández-Montoya, José Carlos Armario-Hita, Manuel Galán-Gutiérrez
Publikováno v:
Life, Vol 14, Iss 3, p 281 (2024)
Introduction: Psoriasis, a chronic inflammatory skin disease, affects 2–10% of the population globally. Bimekizumab (BMK), a monoclonal antibody targeting IL-17, is a dual inhibitor of IL17 A and F that has shown efficacy in treating moderate to se
Externí odkaz:
https://doaj.org/article/8be822c4dc184b10bd295ffbd6afa83b
Autor:
David Martín-Enguix, Ricardo Ruiz-Villaverde, Manuel Galán-Gutiérrez, Ana María Cabrerizo-Carvajal
Publikováno v:
Atención Primaria, Vol 55, Iss 4, Pp 102586- (2023)
Externí odkaz:
https://doaj.org/article/4821101dc5054741845b8ab65ecc70c9
Autor:
Fiorella Vasquez Chinchay, Manuel Galán-Gutiérrez, Jose C. Armario-Hita, Amalia Pérez-Gil, Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire
Publikováno v:
F1000Research, Vol 11 (2022)
Background: Psoriasis is a chronic inflammatory disease which can impact quality of life. In the past decade multiple biologic treatments have been released with encouraging results. Guselkumab is a monoclonal antibody targeting IL-23p19. Multiple ra
Externí odkaz:
https://doaj.org/article/407b086b973448d79f9c3720c708bd7d
Autor:
Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Amalia Pérez-Gil, Pilar Font-Ugalde, Manuel Galán-Gutiérrez
Publikováno v:
Life, Vol 12, Iss 11, p 1883 (2022)
Introduction. Risankizumab is a humanized monoclonal antibody of the immunoglobulin G1 (IgG1) type that binds selectively, and with high affinity, to the p19 subunit of interleukin-23 (IL-23), resulting in the inhibition of inflammation and clinical
Externí odkaz:
https://doaj.org/article/1a9fd6d5f9224841aa9efe41d2646a74
Autor:
Ricardo Ruiz-Villaverde, Fiorella Vasquez-Chinchay, Lourdes Rodriguez-Fernandez-Freire, Jose C. Armario-Hita, Amalia Pérez-Gil, Manuel Galán-Gutiérrez
Publikováno v:
Life, Vol 12, Iss 9, p 1412 (2022)
A fast skin clearance is the main goal to achieve in psoriasis treatment. Patients that present a fast and exceptional improvement with treatment are called super-responders (SR). There is no consensus on the definition of SR with respect to psoriasi
Externí odkaz:
https://doaj.org/article/168265c2256b44b0aeaabfef636ce2a0
Autor:
Ricardo Ruiz-Villaverde, Javier Domínguez-Cruz, Francisco J. Navarro-Triviño, Manuel Galán-Gutiérrez, Jose Carlos Armario-Hita, Jose Juan Pereyra-Rodriguez
Publikováno v:
Life, Vol 12, Iss 8, p 1192 (2022)
In this Special Issue entitled Atopic Dermatitis: New Perspectives, we have tried to collect research of special interest related mainly to the incorporation of pathophysiological aspects and therapeutic novelties in this regard [...]
Externí odkaz:
https://doaj.org/article/41b13841281348f0b3628070ecb49610
Autor:
Angela Ayen-Rodríguez, José-Juan Pereyra-Rodríguez, Francisco J. Navarro-Triviño, Sara Alcantara-Luna, Javier Domínguez-Cruz, Manuel Galán-Gutiérrez, Samuel Vilar-Palomo, Jose Carlos Armario-Hita, Ricardo Ruiz-Villaverde
Publikováno v:
Life, Vol 12, Iss 8, p 1159 (2022)
Introduction: Atopic dermatitis (AD) is a genetically based chronic inflammatory dermatosis associated with multiple triggers and complex pathophysiological mechanisms. Nowadays, an authentic therapeutic revolution is taking place with the incorporat
Externí odkaz:
https://doaj.org/article/9764257d286944cd944aff1356ec20e4
Autor:
José-Juan Pereyra-Rodriguez, Sara Alcantara-Luna, Javier Domínguez-Cruz, Manuel Galán-Gutiérrez, Ricardo Ruiz-Villaverde, Samuel Vilar-Palomo, Jose-Carlos Armario-Hita
Publikováno v:
Life, Vol 11, Iss 9, p 927 (2021)
Background: Some Network Meta-analysis (NMA) has been published regarding atopic dermatitis (AD). These studies have considered drugs under investigation both in monotheraphy or in combination with topical corticosteroids, as well as systemic immunos
Externí odkaz:
https://doaj.org/article/ce853be90c77442287117f0a76d2bc18
Autor:
Francisco Navarro-Triviño, Sara Alcantara-Luna, Javier Domínguez-Cruz, Manuel Galán-Gutiérrez, Ricardo Ruiz-Villaverde, José-Juan Pereyra-Rodriguez, José-Carlos Armario-Hita
Publikováno v:
Immunotherapy.
Atopic dermatitis is an inflammatory skin disease, the prevalence of which has increased in the last decade. It affects all age groups, with adult involvement being a major focus of interest in recent years. The unmet needs of the disease, such as pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c41a761d7ac5e81f64ce0f5f83592d8
https://doi.org/10.2217/imt-2023-0037
https://doi.org/10.2217/imt-2023-0037
Autor:
José-Juan Pereyra-Rodríguez, Pedro Herranz, Ricardo Ruiz-Villaverde, Marta Elosua-González, Manuel Galán-Gutiérrez, Ignasi Figueras-Nart, Javier Miquel, Pablo de la Cueva, Esther Serra-Baldrich, Monica Munera-Campos, Gemma Melé-Ninot, Vicente Expósito-Serrano, Bibiana Perez, Amalia Serrano, Javier F Ortiz de Frutos, José C Armario-Hita
Publikováno v:
Clinical and Experimental Dermatology.
Background Tralokinumab was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) and is the first selective interleukin (IL)-13 inhibitor that specifically neutralizes IL-13 with high affinity. Objectives To determine the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a588f39220d31984807e6ed0b3da363
https://doi.org/10.1093/ced/llad153
https://doi.org/10.1093/ced/llad153